Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 0.57 |
| ▸ | BCR | P11274 | 15/20 | 0.57 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663960 | 0.89 | ABL1 (0.57) | ABL1BCRTNNI3KMEN1KMT2A | |
| SCHEMBL4665773 | 0.88 | CYP1A2 (0.56) | ABL1BCRMEN1KMT2ABACE1 | |
| SCHEMBL4664293 | 0.87 | CYP1A2 (0.58) | ABL1BCRMEN1KMT2ABACE1 | |
| SCHEMBL4663985 | 0.86 | ABL1 (0.61) | ABL1BCRTNNI3K | |
| SCHEMBL4666116 | 0.85 | ABL1 (0.53) | ABL1BCRMEN1KMT2A | |
| SCHEMBL4663856 | 0.82 | ABL1 (0.47) | ABL1BCR | |
| SCHEMBL4665846 | 0.82 | BACE1 (0.59) | ABL1BCRTNNI3KMEN1KMT2A | |
| SCHEMBL4098721 | 0.81 | NPY5R (0.57) | ABL1BCRTNNI3KMEN1KMT2A | |
| SCHEMBL4665772 | 0.81 | CYP1A2 (0.52) | ABL1BCRTNNI3KMEN1KMT2A | |
| SCHEMBL4667395 | 0.81 | CYP1A2 (0.46) | ABL1BCRTNNI3KMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | ABL1 24/4885BCR 402/4885TNNI3K 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.